WO2015199418A3 - 신규한 헤테로고리 화합물 - Google Patents

신규한 헤테로고리 화합물 Download PDF

Info

Publication number
WO2015199418A3
WO2015199418A3 PCT/KR2015/006377 KR2015006377W WO2015199418A3 WO 2015199418 A3 WO2015199418 A3 WO 2015199418A3 KR 2015006377 W KR2015006377 W KR 2015006377W WO 2015199418 A3 WO2015199418 A3 WO 2015199418A3
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclic compound
novel heterocyclic
same
prs
prolyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2015/006377
Other languages
English (en)
French (fr)
Other versions
WO2015199418A2 (ko
Inventor
박준석
윤연정
조민재
이호빈
유자경
이봉용
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daewoong Pharmaceutical Co Ltd
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ727715A priority Critical patent/NZ727715A/en
Priority to ES15812382T priority patent/ES2795368T3/es
Priority to JP2016571347A priority patent/JP6272510B2/ja
Priority to RS20200562A priority patent/RS60264B1/sr
Priority to PL15812382T priority patent/PL3159335T3/pl
Priority to HRP20200785TT priority patent/HRP20200785T1/hr
Priority to US15/312,192 priority patent/US10081634B2/en
Priority to AU2015280874A priority patent/AU2015280874B2/en
Priority to SI201531212T priority patent/SI3159335T1/sl
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Priority to CN201580029527.XA priority patent/CN106458923B/zh
Priority to CA2951798A priority patent/CA2951798C/en
Priority to EP15812382.8A priority patent/EP3159335B1/en
Publication of WO2015199418A2 publication Critical patent/WO2015199418A2/ko
Publication of WO2015199418A3 publication Critical patent/WO2015199418A3/ko
Priority to PH12016502568A priority patent/PH12016502568B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

본 발명은 PRS(prolyl-tRNA synthetase) 활성 이상에 의하여 야기되는 질환의 예방 또는 치료에 사용할 수 있는 하기 화학식 1로 표시되는 화합물, 또는 이의 약학적으로 허용가능한 염, 이의 제조 방법 및 이를 포함하는 약학적 조성물에 관한 것이다.
PCT/KR2015/006377 2014-06-23 2015-06-23 신규한 헤테로고리 화합물 Ceased WO2015199418A2 (ko)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SI201531212T SI3159335T1 (sl) 2014-06-23 2015-06-23 Nova heterociklična spojina
JP2016571347A JP6272510B2 (ja) 2014-06-23 2015-06-23 新規なヘテロ環化合物
RS20200562A RS60264B1 (sr) 2014-06-23 2015-06-23 Novo heterociklično jedinjenje
PL15812382T PL3159335T3 (pl) 2014-06-23 2015-06-23 Nowy związek heterocykliczny
HRP20200785TT HRP20200785T1 (hr) 2014-06-23 2015-06-23 Novi heterociklični spoj
US15/312,192 US10081634B2 (en) 2014-06-23 2015-06-23 Heterocyclic compound
AU2015280874A AU2015280874B2 (en) 2014-06-23 2015-06-23 Novel heterocyclic compound
NZ727715A NZ727715A (en) 2014-06-23 2015-06-23 Novel heterocyclic compounds having prs enzyme inhibitory effect
CN201580029527.XA CN106458923B (zh) 2014-06-23 2015-06-23 杂环化合物
ES15812382T ES2795368T3 (es) 2014-06-23 2015-06-23 Compuesto heterocíclico novedoso
CA2951798A CA2951798C (en) 2014-06-23 2015-06-23 Febrifugine derivatives and their use as prolyl-trna synthetase (prs) inhibitors
EP15812382.8A EP3159335B1 (en) 2014-06-23 2015-06-23 Novel heterocyclic compound
PH12016502568A PH12016502568B1 (en) 2014-06-23 2016-12-21 Novel heterocyclic compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140076674 2014-06-23
KR10-2014-0076674 2014-06-23

Publications (2)

Publication Number Publication Date
WO2015199418A2 WO2015199418A2 (ko) 2015-12-30
WO2015199418A3 true WO2015199418A3 (ko) 2016-04-14

Family

ID=54938901

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/006377 Ceased WO2015199418A2 (ko) 2014-06-23 2015-06-23 신규한 헤테로고리 화합물

Country Status (18)

Country Link
US (1) US10081634B2 (ko)
EP (1) EP3159335B1 (ko)
JP (1) JP6272510B2 (ko)
KR (1) KR102276340B1 (ko)
CN (1) CN106458923B (ko)
AU (1) AU2015280874B2 (ko)
CA (1) CA2951798C (ko)
ES (1) ES2795368T3 (ko)
HR (1) HRP20200785T1 (ko)
HU (1) HUE049482T2 (ko)
MY (1) MY174343A (ko)
NZ (1) NZ727715A (ko)
PH (1) PH12016502568B1 (ko)
PL (1) PL3159335T3 (ko)
PT (1) PT3159335T (ko)
RS (1) RS60264B1 (ko)
SI (1) SI3159335T1 (ko)
WO (1) WO2015199418A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102277538B1 (ko) * 2015-06-08 2021-07-14 주식회사 대웅제약 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물
JP2019196308A (ja) 2016-09-15 2019-11-14 武田薬品工業株式会社 複素環アミド化合物
AR110963A1 (es) 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende
KR102798169B1 (ko) * 2021-12-17 2025-04-21 주식회사 대웅제약 (2R, 3S)-2-(벤조[d]이미다졸일프로필)피페리딘-3-올 유도체의 제조 방법
JP2025529524A (ja) * 2022-10-12 2025-09-04 デウン ファーマシューティカル カンパニー リミテッド 腎臓炎の予防または治療用薬学的組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019210A2 (en) * 2008-08-11 2010-02-18 President And Fellows Of Harvard College Halofuginone analogs for inhibition of trna synthetases and uses thereof
WO2010096170A2 (en) * 2009-02-19 2010-08-26 President And Fellows Of Harvard College Inhibition of trna synthetases and therapeutic applications thereof
WO2013106702A1 (en) * 2012-01-13 2013-07-18 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102277538B1 (ko) 2015-06-08 2021-07-14 주식회사 대웅제약 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019210A2 (en) * 2008-08-11 2010-02-18 President And Fellows Of Harvard College Halofuginone analogs for inhibition of trna synthetases and uses thereof
WO2010096170A2 (en) * 2009-02-19 2010-08-26 President And Fellows Of Harvard College Inhibition of trna synthetases and therapeutic applications thereof
WO2013106702A1 (en) * 2012-01-13 2013-07-18 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CUI, W ET AL.: "Efficient one-pot synthesis of 2-substituted benzimidazoles from triacyloxyborane intermediates", SYNLETT, vol. 23, 2012, pages 247 - 250, XP055335138 *
JAIN, V. ET AL.: "Structure of prolyl-tRNA synthetase-halofuginone complex provides basis for development of drugs against malaria and toxoplasmosis", STRUCTURE, vol. 23, no. 5, 5 May 2015 (2015-05-05), pages 819 - 829, XP029229262, DOI: doi:10.1016/j.str.2015.02.011 *
KELLER, T. L. ET AL.: "Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase", NATURE CHEMICAL BIOLOGY, vol. 8, no. 3, 2012, pages 311 - 317, XP055065300, DOI: doi:10.1038/nchembio.790 *
ROY, P. ET AL.: "One-pot sequential synthesis of 1, 2-disubstituted benzimidazoles under metal-free conditions", TETRAHEDRON LETTERS, vol. 54, no. 38, 2013, pages 5243 - 5245, XP055335135 *
ZHOU, H. ET AL.: "ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase", NATURE, vol. 494, no. 7435, 2013, pages 121 - 125, XP055375882 *

Also Published As

Publication number Publication date
PT3159335T (pt) 2020-06-05
US20170088551A1 (en) 2017-03-30
CA2951798C (en) 2018-07-24
AU2015280874A1 (en) 2017-01-12
CN106458923A (zh) 2017-02-22
MY174343A (en) 2020-04-09
US10081634B2 (en) 2018-09-25
PH12016502568A1 (en) 2017-04-17
HRP20200785T1 (hr) 2020-08-07
JP2017520539A (ja) 2017-07-27
WO2015199418A2 (ko) 2015-12-30
EP3159335B1 (en) 2020-04-29
PL3159335T3 (pl) 2020-10-05
KR102276340B1 (ko) 2021-07-12
EP3159335A4 (en) 2017-11-15
JP6272510B2 (ja) 2018-01-31
NZ727715A (en) 2017-09-29
AU2015280874B2 (en) 2017-12-14
EP3159335A2 (en) 2017-04-26
CA2951798A1 (en) 2015-12-30
PH12016502568B1 (en) 2017-04-17
ES2795368T3 (es) 2020-11-23
CN106458923B (zh) 2019-09-10
SI3159335T1 (sl) 2020-07-31
RS60264B1 (sr) 2020-06-30
HUE049482T2 (hu) 2020-09-28
KR20150146462A (ko) 2015-12-31

Similar Documents

Publication Publication Date Title
PH12019501811A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
WO2016011390A8 (en) Irak4 inhibiting agents
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
PH12016501813A1 (en) 1,3-benzodioxole derivative
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
MY197698A (en) Oxysterols and methods of use thereof
MX2017014035A (es) Formas solidas novedosas.
WO2017106429A3 (en) Bipyrazolyl derivatives useful for the treatment of autoimmune diseases
MY194116A (en) Pharmaceutical compounds
WO2016046260A8 (en) 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators
WO2015001541A3 (en) Pharmaceutical film composition
WO2016004404A3 (en) Gls1 inhibitors for treating disease
PH12016502568B1 (en) Novel heterocyclic compound
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2017214423A3 (en) Derivatives of thailanstatin a, methods of treatment and methods of synthesis thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
PH12017501735A1 (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
WO2017034242A3 (ko) 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물
WO2016020408A3 (en) Compounds for preventing ototoxicity
PH12017502253B1 (en) Imidazodiazepine compound
WO2016044433A3 (en) Metformin derivatives
WO2018080215A8 (en) 3-AMINO ALKYLATED INDOLE DERIVATIVE, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15812382

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 15312192

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2016571347

Country of ref document: JP

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2015812382

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015812382

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2951798

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12016502568

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: IDP00201608904

Country of ref document: ID

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2015280874

Country of ref document: AU

Date of ref document: 20150623

Kind code of ref document: A